XARACOLL Drug Insight and Market Forecast – 2032

XARACOLL Drug Insight and Market Forecast – 2032

“XARACOLL Drug Insight and Market Forecast – 2032” report provides comprehensive insights about XARACOLL for Postoperative Pain in the United States. A detailed picture of the XARACOLL for Postoperative Pain in the United States for the study period 2019–2032 is provided in this report along with a detailed description of the XARACOLL for Postoperative Pain. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XARACOLL market forecast, analysis for Postoperative Pain in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative Pain.

Drug Summary

XARACOLL (bupivacaine HCl) implant is a unique, non-injectable drug-device combination in the form of a fully bioresorbable collagen implant containing bupivacaine hydrochloride that provides postsurgical pain relief through the delivery of bupivacaine, a local anesthetic, at the surgical site. XARACOLL is placed directly into the surgical site during surgery and, after placement, releases bupivacaine immediately and over time.

XARACOLL was approved in August 2020 by the US Food and Drug Administration (FDA). XARACOLL is indicated in adults for placement into the surgical site to produce postsurgical local analgesia for up to 24 h following open inguinal hernia repair. The drug contains a local amide anesthetic and is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 h following open inguinal hernia repair.

As per the company, XARACOLL is launched through a partnership between Mallinckrodt Pharmaceutical’s Acute Care Sales Team and Innocoll’s Hospital Sales Team.

Dosage and administration

The recommended dose is 300 mg bupivacaine HCl (three XARACOLL implants, each containing 100 mg bupivacaine HCl).

Mechanism of Action

Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential. Clinically, the order of a loss of nerve function is (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the XARACOLL description, mechanism of action, dosage and administration, research and development activities in Postoperative Pain.

Elaborated details on XARACOLL regulatory milestones and other development activities have been provided in this report.

The report also highlights the XARACOLL research and development activity in Postoperative Pain in detail across the United States.

The report also covers the patents information with expiry timeline around XARACOLL.

The report contains forecasted sales of XARACOLL for Postoperative Pain till 2032.

Comprehensive coverage of the late-stage emerging therapies for Postoperative Pain.

The report also features the SWOT analysis with analyst views for XARACOLL in Postoperative Pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XARACOLL Analytical Perspective by DelveInsight

In-depth XARACOLL Market Assessment

This report provides a detailed market assessment of XARACOLL in Postoperative Pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

XARACOLL Clinical Assessment

The report provides the clinical trials information of XARACOLL in Postoperative Pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Postoperative Pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XARACOLL dominance.

Other emerging products for Postoperative Pain are expected to give tough market competition to XARACOLL and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XARACOLL in Postoperative Pain.

Our in-depth analysis of the forecasted sales data of XARACOLL from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XARACOLL in Postoperative Pain.

Key Questions

What is the product type, route of administration and mechanism of action of XARACOLL?

What is the clinical trial status of the study related to XARACOLL in Postoperative Pain and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XARACOLL development?

What are the key designations that have been granted to XARACOLL for Postoperative Pain?

What is the forecasted market scenario of XARACOLL for Postoperative Pain?

What are the forecasted sales of XARACOLL in the United States?

What are the other emerging products available in Postoperative Pain and how are they giving competition to XARACOLL for Postoperative Pain?

Which are the late-stage emerging therapies under development for the treatment of Postoperative Pain?